Exelixis (EXEL) Tops Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Exelixis (EXEL) Tops Q1 EPS by 4c

Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update

May 1, 2019 4:05 PM EDT

- Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million -

- GAAP Diluted EPS of $0.24, Non-GAAP Diluted EPS of $0.27 -

- Conference Call and Webcast Today at 5:00 PM Eastern Time -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

The first quarter of 2019... More